Antitumor effect of BPR-DC-2, a novel synthetic cyclic cyanoguanidine derivative, involving the inhibition of MDR-1 expression and down-regulation of p-AKT and PARP-1 in lung cancer Shun-Lai LiChia-Hsin HuangJiunn-Jye Chuu PRECLINICAL STUDIES 05 December 2009 Pages: 195 - 206
Astaxanthin inhibits tumor invasion by decreasing extracellular matrix production and induces apoptosis in experimental rat colon carcinogenesis by modulating the expressions of ERK-2, NFkB and COX-2 Ponnuraj NagendraprabhuGanapasam Sudhandiran PRECLINICAL STUDIES 30 October 2009 Pages: 207 - 224
Inhibitory effects of tea polyphenols by targeting cyclooxygenase-2 through regulation of nuclear factor kappa B, Akt and p53 in rat mammary tumors Preeti RoyJasmine GeorgeYogeshwer Shukla PRECLINICAL STUDIES 20 November 2009 Pages: 225 - 231
CYT997 Causes apoptosis in human multiple myeloma Katherine MonaghanTiffany KhongAndrew Spencer PRECLINICAL STUDIES 12 November 2009 Pages: 232 - 238
Selective proapoptotic activity of polyphenols from red wine on teratocarcinoma cell, a model of cancer stem-like cell Tanveer SharifCyril AugerGuy Fuhrmann PRECLINICAL STUDIES 27 November 2009 Pages: 239 - 247
Cellular pharmacology of multi- and duplex drugsconsisting of ethynylcytidine and 5-fluoro-2′-deoxyuridine Irene V. BijnsdorpReto A. SchwendenerGodefridus J. Peters PRECLINICAL STUDIES Open access 03 December 2009 Pages: 248 - 257
Oleanolic acid derivative Dex-OA has potent anti-tumor and anti-metastatic activity on osteosarcoma cells in vitro and in vivo Yingqi HuaZhiyu ZhangZhengdong Cai PRECLINICAL STUDIES 27 November 2009 Pages: 258 - 265
Lupane Triterpenoids—Betulin and Betulinic acid derivatives induce apoptosis in tumor cells Harish KommeraGoran N. KaluđerovićReinhard Paschke PRECLINICAL STUDIES 04 December 2009 Pages: 266 - 272
Luteolin inhibits cell proliferation during Azoxymethane-induced experimental colon carcinogenesis via Wnt/ β-catenin pathway Pandurangan AshokkumarGanapasam Sudhandiran PRECLINICAL STUDIES 15 December 2009 Pages: 273 - 284
Dibutyltin(IV) complexes containing arylazobenzoate ligands: chemistry, in vitro cytotoxic effects on human tumor cell lines and mode of interaction with some enzymes Tushar S. Basu BaulAnup PaulEdward R. T. Tiekink PRECLINICAL STUDIES 11 December 2009 Pages: 285 - 299
Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4′,5-trimethoxylstilbene-3′-O-phosphate disodium (M410) Yu-Chen CaiYong ZouLi-Jian Xian PRECLINICAL STUDIES 11 December 2009 Pages: 300 - 311
Temporal evolution of patient characteristics enrolled on phase I trials Afshin DowlatiMadappa KundrandaPingfu Fu PHASE I STUDIES 09 December 2009 Pages: 312 - 315
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies Anne M. TraynorJames P. ThomasHoward H. Bailey PHASE I STUDIES 09 December 2009 Pages: 316 - 322
A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia Isam Abdel-KarimWilliam K. Plunkett JrHagop M. Kantarjian PHASE I STUDIES 21 January 2010 Pages: 323 - 331
A phase I study of S-1 treatment with a 3 week schedule in advanced biliary cancer patients with or without hepatic dysfunction Dok Hyun YoonHyo Jung LeeTae Won Kim PHASE I STUDIES 30 December 2009 Pages: 332 - 339
A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer Qing ZhouDaniel GustafsonD. Ross Camidge PHASE I STUDIES 19 January 2010 Pages: 340 - 346
Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer Bhuvaneswari RamaswamyEwa MrozekEric H. Kraut PHASE II STUDIES 21 October 2009 Pages: 347 - 351
Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618 Susanne M. ArnoldJames MoonSusan G. Urba PHASE II STUDIES 25 November 2009 Pages: 352 - 359
Phase II study of vinorelbine monotherapy in anthracycline and taxane pre-treated metastatic breast cancer Hee Yeon SeoHyun Joo LeeJae Hong Seo PHASE II STUDIES 27 November 2009 Pages: 360 - 365
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer Chul KimJae-Lyun LeeYoon-Koo Kang PHASE II STUDIES 09 December 2009 Pages: 366 - 373
A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma Christopher W. RyanJacqueline VukyDeirdre Nauman PHASE II STUDIES 10 December 2009 Pages: 374 - 379
Chemopreventive doses of resveratrol do not produce cardiotoxicity in a rodent model of hepatocellular carcinoma Daniel J. LutherVahagn OhanyanAnupam Bishayee SHORT REPORT 08 October 2009 Pages: 380 - 391
Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell lines Claudio CeleghiniRebecca VoltanGiorgio Zauli SHORT REPORT 04 February 2010 Pages: 392 - 395
Sphingosine-1-phosphate: a potential therapeutic agent against human breast cancer Binbing LingLifeng ChenJian Yang SHORT REPORT 30 December 2009 Pages: 396 - 399